ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

被引：20
|
作者：
Gettinger, S. [1 ]
Bazhenova, L. [2 ]
Salgia, R. [3 ]
Langer, C. [4 ]
Gold, K. [5 ]
Rosell, R. [6 ]
Shaw, A. [7 ]
Weiss, G. J. [8 ]
Narasimhan, N. I. [9 ]
Dorer, D. J. [10 ]
Rivera, V. M. [11 ]
Clackson, T. [12 ]
Haluska, F. G. [13 ]
Camidge, R. [14 ]
机构：
[1] Yale Univ, Sch Med, Thorac Oncol Program, New Haven, CT USA
[2] UCSD Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] USP Dexeus Univ Inst, Inst Oncol Dr Rosell, Med Oncol Serv, Barcelona, Spain
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[9] ARIAD Pharmaceut Inc, DMPK, Cambridge, MA USA
[10] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA USA
[11] ARIAD Pharmaceut, Preclin & Translat Res, Cambridge, MA USA
[12] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA
[13] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA USA
[14] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu349.71
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1292P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [42] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK plus Advanced Non-Small Cell Lung Cancer (NSCLC)
    Du Tertre, M. Couetoux
    Marques, M.
    Izzi, L.
    Tremblay, L.
    Bouchard, N.
    Diaconescu, R.
    Blais, N.
    Hoffert, C.
    Srivastava, A.
    McNamara, S.
    Batist, G.
    Cohen, V.
    Agulnik, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S673 - S673
  • [44] Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel Shao-Weng
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin H.
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Boral, Anthony
    Yovine, Alejandro Javier
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Indirect Naive Comparison of ALK Inhibitors for ALK plus Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure
    Reckamp, Karen L.
    Huang, Joice
    Huang, Hui
    Moore, Yan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S313 - S314
  • [46] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Outcomes of ALK plus non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the clinical trial setting and in a referral Institution.
    Rojo, Ana Matres
    Felip, Enriqueta
    Dienstmann, Rodrigo
    Garces, Victor Navarro
    Viaplana, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
    Le, H.
    Coulter, J.
    Cappelleri, J. C.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Culver, K.
    Vaghela, S.
    Rifi, N.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S202 - S202
  • [50] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
12345